DEC 19, 2019 11:02 AM PST

Upcoming Psychedelic Cure for Addiction Derived from African Shrub

WRITTEN BY: Annie Lennon

Every year, almost 70,000 people die from an overdose in the US. Now, a company called MindMed is testing a compound derived from ibogaine, a West African hallucinogen, to fight addiction.

Ibogaine first came to the attention of the West in the 1960’s, when heroin-addicted Howard Lotsof and six similarly-dependent friends tripped on the substance for two days. Afterwards, out of the seven, five of Lostof’s party were no longer addicted to heroin. Impressed by its properties, Lostof created a foundation and began reaching out to researchers and politicians to test out the substance. 

These calls soon caught the attention of Stan Glick, a researcher at Albany Medical Center, who then conducted trials for ibogaine on morphine-addicted rats. While on the drug, he noted how the rats would convulse for hours, likely due to hallucinations. Just a day later however, when the hallucinations and convulsing had ceased, they found that the rats’ cravings for morphine had either significantly reduced, or subsided completely. 

Although effective in relieving addiction, further studies revealed it had some unintended side effects such as vomiting and slowing the heart rate, to a lethal effect in some cases. With such consequences rendering the drug unfit for public use, Gluck then endeavoured to isolate its compounds to eliminate these negative effects. 

Eventually stumbling across 18-MC, he created a company to properly explore its properties. From initial trials, Glick found that the substance is unique in its way of regulating addictive behavior. Unlike addictive drugs such as alcohol or cocaine that increase dopamine release, 18-MC modulates its release via a set of different neural pathways. Glick said, “That’s why I think it works on multiple drugs, because it’s not focused on a specific action in the dopamine pathway.” 

Running out of funding, Glick’s company was eventually bought by MindMed in June 2019 to continue research into the substance. Known to exclude the hallucinogenic “trip”, some are skeptical on its healing abilities given that many report it is the “trip” that allows them to rid themselves of addiction cycles with other psychedelic medicines. 

Seemingly effective nevertheless, the company plans to run safety trials on the compound during the second half of 2020, and then efficacy trials by the fourth quarter. As it is not a classified drug such as LSD and psilocybin, MindMed hopes that 18-MC may have an expedited route to becoming widely available as atreatment for addiction.


Sources: Fast Company and The Observer

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 17, 2020
Cell & Molecular Biology
MAY 17, 2020
Potential Treatment for Brain and Spinal Cord Injury is IDed
Treatment options are limited for people that have suffered swelling-inducing injuries to their brain and spinal cord. N ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
MAY 28, 2020
Cannabis Sciences
MAY 28, 2020
Cannabis-Free CBD More Effective than Regular CBD
Commonly known to come from the cannabis plant or hemp, cannabidiol (CBD) can also be found in a range of other plants. ...
JUN 04, 2020
Cancer
JUN 04, 2020
Inhibiting the Signals Critical for Cancer Growth in Merkel Cell Carcinoma
Merkel Cell Carcinoma (MCC) is a highly aggressive cancer of the skin. It is characterized by a high recurrence rate and ...
JUN 06, 2020
Cancer
JUN 06, 2020
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
Cancer has been one of the most persistent diseases modern medicine has faced. Due to its nature, treatments are often t ...
JUN 22, 2020
Drug Discovery & Development
JUN 22, 2020
MDMA Has Long-Term Benefits Against PTSD
Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-t ...
Loading Comments...